Thermo Fisher Scientific: Recovery In Life Sciences Solutions

2026-03-02 13:29:57 ET

I reiterated a ‘buy’ rating on Thermo Fisher Scientific ( TMO ) on August 6, 2025, highlighting its business strength in the pharma and biotech markets. The company delivered 3% organic revenue growth in Life Science Solutions in FY25, demonstrating a gradual recovery in the broader biotech and pharmaceutical industries. I favor the company’s acquisition of Clario Holdings, as it could further strengthen Thermo Fisher Scientific’s laboratory products and biopharma services. I reiterate a ‘buy’ rating on Thermo Fisher Scientific with a fair value of $619 per share....

Read the full article on Seeking Alpha

For further details see: